Close Menu

tender offer

The amounts to be purchased of each of six separate classes of notes will be determined in accordance with the acceptance priority level determined by Roche.

BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.

Thermo Fisher said that it received notice that TRC Capital made an unsolicited mini-tender offer to purchase up to 1 million shares of its stock at $181.75 per share. 

The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.

Abbott's tender offer to purchase all outstanding shares of Alere's Series B convertible perpetual preferred stock at $402 per share is now scheduled to expire on Oct. 3. 

The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.

LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.

Agilent received notice of an unsolicited mini-tender offer by TRC Capital to purchase up to 2.5 million shares of Agilent's shares at a discount to market price.

Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock.

Roche said that based on preliminary results, Foundation Medicine shareholders tendered a total of 17.5 million shares, not including 1.9 million shares that were tendered by notice of guaranteed delivery.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.